Table of Contents
OVERVIEW
EXECUTIVE SUMMARY
- Strategic scoping and focus
- Datamonitor insight into the disease market
- Related reports
- Upcoming related reports
PIPELINE OVERVIEW AND DYNAMICS
- Key findings
- Pipeline overview
- Extensive pipeline highlights commercial interest in rheumatoid arthritis
- Comparatively few products have made it to Phase III
- Comparative forecasts - pipeline products generate multi-billion
dollar boost to the market
- Datamonitor pipeline assessment summary - Actemra/RoActemra will be
well placed for market success
- Key companies involved in the rheumatoid arthritis pipeline
- Roche - Genentech acquisition solidifies its position as a major
player in rheumatoid arthritis
- Pfizer - extensive pipeline with the most advanced kinase inhibitor
for rheumatoid arthritis
- Bristol-Myers Squibb - looking beyond Orencia
- Key R&D company strategies
- Focus on oral, small molecule formulations
- Companies are going for dual subcutaneous and intravenous delivery
formulations
RHEUMATOID ARTHRITIS - MARKET POTENTIAL
- Key findings
- Definition
- ICD-10 codes used to define the rheumatoid arthritis market
- Patient segmentation
- Early active rheumatoid arthritis
- Antibody positive rheumatoid arthritis
- TNF-failure patients
- Juvenile idiopathic arthritis
- Epidemiology
- Seven major markets
- Rest of the world
- Current treatment options
- Traditional DMARDs
- Anti-TNFs
- B cell therapies
- T cell co-stimulator modulators
- Current gold standard and comparator therapies
- Methotrexate remains the gold-standard for rheumatoid arthritis
- Comparator therapies
- Current market overview
- Minimal growth in seven major market rheumatoid arthritis sales between
2007 and 2008
- Anti-TNF sales were down in 2008, but alternative biologics experienced
good uptake in 2007 - 08
- Orencia and Rituxan lead year-on-year growth from 2007 to 2008
- Unmet needs in rheumatoid arthritis
- Better clinical response
- Early diagnosis and early treatment
- Identifying patients who will respond to therapies
- Establish optimal treatment strategies for TNF-failure patients
- Oral, small molecules that fill the gap between DMARDs and biologics
- Understand the impact of combining therapies
- Treatments and strategies to stop the disease early then stop drug
therapy
- Options for patients who fail all the biologics
- Current level of attainment vs. target product profile
- Efficacy
- Safety
- Formulation
- Cost
R&D APPROACH
- Key findings
- Clinical trial design in rheumatoid arthritis
- Shift towards patient recruitment from Eastern Europe and South America
for clinical trials
- Trial design
- Clinical trial endpoint measures
PIPELINE ANALYSIS & FORECASTS: TNF INHIBITORS
- Key findings
- Overview for TNF inhibitors
- Pipeline summary
- Comparative forecasts
- Simponi (golimumab; Centocor Ortho Biotech/Schering-Plough/Mitsubishi
Tanabe)
- Drug overview
- Drug profile
- Clinical trial data
- SWOT analysis
- Datamonitor drug assessment score card for Simponi
- Clinical and commercial attractiveness
- Satisfaction of unmet needs
- Forecasts to 2018
- Cimzia (certolizumab; UCB, Otsuka Pharmaceuticals)
- Drug overview
- Drug profile
- Clinical trial data
- SWOT analysis
- Datamonitor drug assessment score card for Cimzia
- Clinical and commercial attractiveness
- Satisfaction of unmet needs
- Forecasts to 2018
- Other drugs in TNF inhibitor class
- ART621 (Domantis [GlaxoSmithKline]/Arana Therapeutics)
- TNF alpha kinoid (Neovacs)
- Late-stage development compounds recently discontinued
- Key early-stage and preclinical compounds in TNF inhibitors
PIPELINE ANALYSIS & FORECASTS: B CELL TARGETS
- Key findings
- Overview for B Cell targets
- Pipeline summary
- Comparative forecasts
- Ocrelizumab (Genentech, Biogen Idec, Roche and Chugai)
- Drug overview
- Drug profile
- Clinical trial data
- SWOT analysis
- Datamonitor drug assessment score card for ocrelizumab
- Clinical and commercial attractiveness
- Satisfaction of unmet needs
- Forecasts to 2018
- Arzerra (ofatumumab; Genmab, GlaxoSmithKline)
- Drug overview
- Drug profile
- Clinical trial data - Phase III
- Clinical trial data - Phase II
- SWOT analysis
- Datamonitor drug assessment score card for Arzerra
- Clinical and commercial attractiveness
- Satisfaction of unmet needs
- Forecasts to 2018
- Other drugs in B Cell targets class
- Atacicept (TACI-Ig; ZymoGenetics, Merck Serono)
- Benlysta (belimumab; Human Genome Sciences, GlaxoSmithKline)
- TRU-015 (Trubion Pharmaceuticals, Wyeth/Pfizer)
- LY2127399
- Veltuzumab (IMMU106; Immunomedics)
- B cell targets recently discontinued
- Briobacept (BR3-Fc; Biogen Idec, Genentech)
- Key early-stage and preclinical compounds in B cell targets class
PIPELINE ANALYSIS & FORECASTS: OTHER CYTOKINE ANTAGONISTS
- Key findings
- Overview for other cytokine antagonists
- Actemra/RoActemra (tocilizumab; Chugai, Roche)
- Drug overview
- Drug profile
- Clinical trial data
- SWOT analysis
- Datamonitor drug assessment score card for Actemra
- Clinical and commercial attractiveness
- Satisfaction of unmet needs
- Forecasts to 2018
- Other drugs in cytokine antagonists
- Canakinumab (Ilaris, ACZ885; Novartis)
- Iguratimod (T-164, Careram; Toyama Chemical; Eisai)
- Denosumab (AMG162; Amgen)
- AMG108 (Amgen)
- CNTO136 (Centocor Ortho Biotech)
- Anti IL-17 antibody (LY2439821; Eli Lilly)
- K832 (Kowa Pharmaceuticals)
- AIN457 (Novartis)
- Apilimod (STA5326; Synta Pharmaceuticals)
- XOMA052 (Xoma)
- ALD-518 (Alder Biopharmaceuticals)
- Givinostat (ITF2357; Italfarmaco)
- Late-stage development compounds recently discontinued
- AZD5672
- MLN-3897
- LY2189102
- Key early-stage and preclinical compounds in cytokine antagonist class
PIPELINE ANALYSIS & FORECASTS: KINASE INHIBITORS
- Key findings
- Overview for kinase inhibitors
- Pipeline summary
- Comparative forecasts
- CP-690,550 (Pfizer)
- Drug overview
- Drug profile
- Clinical trial design - Phase III
- Clinical trial design and data - Phase II
- SWOT analysis
- Datamonitor drug assessment score card for CP-690,550
- Clinical and commercial attractiveness
- Satisfaction of unmet needs
- Forecasts to 2018
- R788 (Fostamatinib disodium; Rigel Pharmaceuticals)
- Drug overview
- Drug profile
- Clinical trial data - Phase II trial data mixed, but Datamonitor is
positive
- SWOT analysis
- Datamonitor drug assessment score card for R788
- Clinical and commercial attractiveness
- Satisfaction of unmet needs
- Forecasts to 2018
- Other drugs in the kinase inhibitors class
- Masitinib (AB1010; AB Science)
- ARRY162 (ARRY-438162; Array BioPharma)
- BMS-582949 (Pharmacopeia, Bristol-Myers Squibb)
- GW856553 (GlaxoSmithKline)
- INCB18424 (Incyte)
- INCB28050 (Incyte)
- PH797804
- Late-stage development compounds recently discontinued
- P38 MAP kinase inhibitors showing high attrition rate in rheumatoid
arthritis
PIPELINE ANALYSIS & FORECASTS: OTHERS
- Key findings
- Overview for Others
- dnaJp1 (Adeona Pharmaceuticals)
- T-5224 (Toyama Chemical)
- 4SC-101 (SC-12267; 4SC)
- BT061 (Biotest)
- CH1504 (Chelsea Therapeutics)
- Tranilast (Nuon Therapeutics)
- MDX-1100 (Medarex (Bristol-Myers Squibb)
- MM093 (GTC Biotherapeutics/Merrimack Pharmaceuticals)
- Rabeximod (Rob803; OxyPharma)
- PG760564 (Proctor & Gamble)
- RWJ-445380 (ALZA Corp, Johnson & Johnson)
- LX-2931 (LX-3305; Lexicon Pharmaceuticals)
- Fezakinumab (ILV-094; Wyeth [now Pfizer])
- PI2301 (Peptimmune)
- Late-stage development compounds recently discontinued
- Recent high-profile discontinuations highlight P2X7 antagonism may not
be successful target
- Key early-stage and preclinical compounds in Others class
INNOVATIVE EARLY-STAGE APPROACHES
- Key findings
- Overview of early-stage innovative projects
- Kinase inhibitors represent a large proportion of the drugs in early
phase development
- The anti-GM-CSF strategy: the next promising target?
- NFKappaB
- Chemokine receptor antagonists
- The future of treatment in rheumatoid arthritis
- Combining therapies will be commonplace in future treatment of
rheumatoid arthritis
- Biomarkers to predict response to biologic therapy
BIBLIOGRAPHY
- Journals
- Websites
- Datamonitor reports
- Other sources
APPENDIX
- Methodology
- Datamonitor forecast methodology
- Datamonitor drug assessment scorecard methodology
- Contributing experts
TABLES
- Table: Late-phase pipeline products in development for rheumatoid
arthritis, 2009
- Table: Sales forecasts for pipeline products in late-stage development in
rheumatoid arthritis in the seven major markets ($m), 2009 - 2018
- Table: Roche' s rheumatoid arthritis marketed and pipeline product
portfolio, 2009
- Table: Pfizer' s rheumatoid arthritis pipeline portfolio, 2009
- Table: Bristol-Myers Squibb' s rheumatoid arthritis pipeline portfolio, 2009
- Table: Pipeline products with both subcutaneous and intravenous
formulations in potential development for rheumatoid arthritis, 2009
- Table: Datamonitor' s definition of rheumatoid arthritis
- Table: Efficacy of common medication used to treat juvenile idiopathic
arthritis, 2009
- Table: Marketed and pipeline products for juvenile idiopathic arthritis,
2009
- Table: Incidence rates (cases/1,000) of rheumatoid arthritis worldwide in
studies based on ACR criteria, 1993 - 2002
- Table: Prevalence of rheumatoid arthritis across the seven major markets,
2010
- Table: Estimated total rheumatoid arthritis (RA) populations in each of
the seven major markets, 2010 - 2020
- Table: Epidemiology studies into juvenile idiopathic arthritis (JIA), 1987
- 2007
- Table: Estimated juvenile idiopathic arthritis (JIA) prevalence and
population across the seven major markets, 2010
- Table: Estimated juvenile idiopathic arthritis (JIA) population in the
seven major markets, 2010 - 2020
- Table: Datamonitor' s estimated prevalence figures for rheumatoid arthritis
in regions outside the seven major markets, 2009
- Table: Leading treatments for rheumatoid arthritis, 2009
- Table: Enbrel (etanercept) - Drug profile, 2009
- Table: Ability of current comparator Enbrel to meet unmet needs in
rheumatoid arthritis, 2009
- Table: ACR scores in biologic-naive versus TNF-failure rheumatoid
arthritis patients
- Table: Key products in the late-stage R&D pipeline for TNF inhibitors for
rheumatoid arthritis, 2009
- Table: Sales forecasts for new TNF inhibitors in rheumatoid arthritis in
the seven major markets ($m), 2008 - 2018
- Table: Simponi - Drug profile, 2009
- Table: Simponi (golimumab): Efficacy results in patients previously
receiving anti-TNFs for rheumatoid arthritis, 2009
- Table: Simponi (golimumab): efficacy data for intravenous Simponi
(golimumab) at week 14, week 24 and week 48 in rheumatoid arthritis, 2009
- Table: Simponi versus TNF inhibitor comparator therapy Enbrel in
rheumatoid arthritis - minimum acceptable product profile (MAPP) and target
product profile (TPP), 2009
- Table: Simponi (golimumab): sales forecasts in the seven major markets
($m), 2009 - 2018
- Table: Cimzia - Drug profile, 2009
- Table: Cimzia versus TNF inhibitor comparator therapy Enbrel in rheumatoid
arthritis - minimum acceptable product profile and target product profile,
2009
- Table: Cimzia (certolizumab): sales forecasts for in the seven major
markets ($m), 2009 - 2018
- Table: Neovacs' s kinoid active antibody therapy: advantages compared to
standard monoclonal antibody therapy
- Table: Key products in the early-stage R&D pipeline for TNF inhibitors,
2009
- Table: Key products in the late-stage R&D pipeline for B Cell targets for
rheumatoid arthritis, 2009
- Table: Sales forecasts for B cell therapies in the seven major markets
($m), 2009 - 2018
- Table: Ocrelizumab - Drug profile, 2009
- Table: Ocrelizumab: Phase III clinical trial program in rheumatoid
arthritis, 2009
- Table: Ocrelizumab versus comparator therapy Enbrel in rheumatoid
arthritis - minimum acceptable product profile and target product profile,
2009
- Table: Ocrelizumab: sales forecasts in the seven major markets ($m), 2009
- 2018
- Table: Arzerra - Drug profile, 2009
- Table: Arzerra (ofatumumab): ongoing Phase III and Phase I/IIa trials in
rheumatoid arthritis, 2009
- Table: Arzerra (ofatumumab): week 48 follow-up data for Phase II trial in
DMARD-failure rheumatoid arthritis patients, 2008
- Table: Arzerra (ofatumumab) versus comparator therapy Enbrel in rheumatoid
arthritis - minimum acceptable product profile and target product profile,
2009
- Table: Arzerra (ofatumumab): sales forecasts in the seven major markets
($m), 2009 - 2018
- Table: Atacicept (TACI-Ig); summary of Phase II clinical trials in
rheumatoid arthritis, 2009
- Table: Key early-stage compounds targeting B cells in rheumatoid arthritis
in 2009.
- Table: Key products in the late-stage R&D pipeline for cytokine
antagonists for rheumatoid arthritis, 2009
- Table: Actemra/RoActemra - Drug profile, 2009
- Table: Actemra (tocilizumab) versus cytokine antagonist comparator therapy
Enbrel - minimum acceptable product profile and target product profile, 2009
- Table: Actemra/RoActemra (tocilizumab): sales forecasts in the seven major
markets ($m), 2008 - 2018
- Table: Denosumab (AMG162): MRI erosion score at 6 months and clinical
efficacy scores at 12 months from the Phase II study in rheumatoid arthritis,
2008
- Table: AIN457: proof-of-concept study results in rheumatoid arthritis, 2009
- Table: Key early-stage and preclinical compounds in the cytokine
antagonist class in development for rheumatoid arthritis, 2009
- Table: Key products in the late-stage R&D kinase inhibitor pipeline for
rheumatoid arthritis., 2009
- Table: Sales forecasts for kinase inhibitors in the seven major markets
($m), 2009 - 2018
- Table: CP-690,550 - Drug profile, 2009
- Table: CP-690,550: Summary of ongoing, recruiting Phase III rheumatoid
arthritis trials, 2009
- Table: CP-690,550: summary of ongoing, recruiting Phase II rheumatoid
arthritis trials , 2009
- Table: CP-690,550: Phase II clinical trial information for completed
studies, 2009
- Table: CP-690,550: A3921035 and A3921025 trial data, 2009
- Table: CP-690,550 versus TNF inhibitor comparator therapy Enbrel in
rheumatoid arthritis - minimum acceptable product profile and target product
profile, 2009
- Table: CP-690,550: sales forecasts in the seven major markets ($m), 2009 -
2018
- Table: R788 - Drug profile, 2009
- Table: R788 versus comparator therapy Enbrel in rheumatoid arthritis,
minimum acceptable product profile and target product profile, 2009
- Table: R788: sales forecasts in the seven major markets ($m), 2009 - 2018
- Table: Masitinib (AB1010): Summary of efficacy outcomes at week 12 with
subgroup analysis according to previous treatment failure, 2009
- Table: ARRY162: clinical trial efficacy results(ARRAY-162-201) - ACR20
scores at week 12 across geographic regions, 2009
- Table: ARRY162: clinical trial safety results ARRAY-162-201) - most
common adverse events, 2009
- Table: GW856553: Completed Phase II trials in rheumatoid arthritis, 2008
- Table: SCIO469' s Phase II trial results in rheumatoid arthritis, 2008
- Table: Key products in the late-stage R&D pipeline for Others for
rheumatoid arthritis, 2009
- Table: 4SC-101: Phase IIa clinical trial data in rheumatoid arthritis
patients who previously failed treatment with DMARDs, 2007
- Table: Key early-stage products in the R&D pipeline for Others, 2009
- Table: Early-stage candidates targeting granulocyte-macrophage colony
stimulating factor in development for rheumatoid arthritis, 2009
- Table: NF-kappaB inhibitors in early-stage development for rheumatoid
arthritis, 2009
- Table: Chemokine receptor antagonists in early-stage development for
rheumatoid arthritis, 2009
- Table: Datamonitor drug assessment parameters
FIGURES
- Figure: Rheumatoid arthritis pipeline split by highest development phase
and drug class, 2009
- Figure: Datamonitor' s pipeline assessment summary for rheumatoid
arthritis, 2009
- Figure: Rheumatoid arthritis pipeline split by formulation, and type of
molecule for oral products, 2009
- Figure: Datamonitor' s strategy for switching between intravenous and
subcutaneous formulations in rheumatoid arthritis, 2009
- Figure: Datamonitor' s methodology for calculating rheumatoid arthritis
specific sales from IMS total brand sales and volume data
- Figure: Datamonitor' s estimated number of rheumatoid arthritis patients
receiving biologic therapy as anti-TNFs or alternative mechanisms in the seven
major markets, 2007 - 2017
- Figure: Classification of juvenile idiopathic arthritis (JIA), 2009
- Figure: Age-adjusted incidence of rheumatoid arthritis in Rochester,
Minnesota, 1955 - 2005
- Figure: Top 5 Rest of World countries with highest prevalent populations
of rheumatoid arthritis, 2009 - 2019
- Figure: Rheumatoid arthritis-specific sales in the seven major markets,
split by region ($ billion), 2004 - 08
- Figure: Rheumatoid arthritis-specific sales in the seven major markets,
split by drug class ($ billion), 2004 - 08
- Figure: Performance of the top 10 brands/molecules and All Others in the
seven major rheumatoid arthritis markets, 2004 - 08
- Figure: Key unmet needs in rheumatoid arthritis, 2009
- Figure: Orencia versus Humira head-to-head clinical trial design in
rheumatoid arthritis (RA), 2009
- Figure: EULAR response criteria as defined by DAS28
- Figure: Datamonitor drug assessment summary for tumor necrosis factor
(TNF) inhibitors in development for rheumatoid arthritis, 2009
- Figure: Simponi (golimumab): GO-FORWARD: Clinical trial design and results
at week 14 in rheumatoid arthritis (RA), 2008
- Figure: Simponi (golimumab): GO-BEFORE: Clinical trial design and results
at week 24 in rheumatoid arthritis (RA), 2008
- Figure: Simponi (golimumab): GO-AFTER: Clinical trial design and results
at week 14 in rheumatoid arthritis, 2008
- Figure: Simponi (golimumab): Phase III study design for intravenous dose
in rheumatoid arthritis, 2009
- Figure: Simponi SWOT analysis, 2009
- Figure: Datamonitor' s competitive positioning analysis of Simponi
(golimumab), 2009
- Figure: Cimzia (certolizumab): UCB' s RAPID 1 trial in rheumatoid arthritis
patients who failed methotrexate therapy, 2008
- Figure: Cimzia (certolizumab): UCB' s RAPID 2 trial in rheumatoid arthritis
patients who failed methotrexate therapy, 2009
- Figure: Cimzia (certolizumab): UCB' s FAST4WARD trial as a monotherapy in
rheumatoid arthritis patients who failed DMARD therapy, 2009
- Figure: Cimzia SWOT analysis, 2009
- Figure: Datamonitor' s competitive positioning analysis of Cimzia
(certolizumab), 2009
- Figure: ART621: Phase II clinical trial design in rheumatoid arthritis
dose optimization study, 2009
- Figure: ART621: Phase II clinical trial design in rheumatoid arthritis
dose ranging study, 2009
- Figure: Datamonitor drug assessment summary for B cell targets in
development for rheumatoid arthritis, 2009
- Figure: Ocrelizumab: efficacy data from Phase II ACTION trial in
rheumatoid arthritis , 2007
- Figure: Ocrelizumab: Phase III trial in Japanese rheumatoid arthritis
patients who have failed therapy with anti-TNFs, 2009
- Figure: Ocrelizumab: Phase II trial in Japanese rheumatoid arthritis
patients, 2009
- Figure: Ocrelizumab: SWOT analysis, 2009
- Figure: Datamonitor' s competitive positioning analysis of ocrelizumab, 2009
- Figure: Arzerra (ofatumumab): week 24 ACR scores in DMARD-failure
rheumatoid arthritis patients, 2007
- Figure: Arzerra (ofatumumab): SWOT analysis, 2009
- Figure: Datamonitor' s competitive positioning analysis of Arzerra
(ofatumumab), 2009
- Figure: Benlysta (belimumab): LBRA01 Phase II clinical trial design and
summary of results for rheumatoid arthritis, 2005
- Figure: TRU-015: Phase IIb Study Two clinical trial design for rheumatoid
arthritis, 2009
- Figure: TRU-015: Phase IIb Study One clinical trial design summary and
trial results for rheumatoid arthritis
- Figure: TRU-015: Phase IIb Study One - open label retreatment data with
800mg TRU-015 for rheumatoid arthritis
- Figure: LY2127399 (IV): trial design and results of first Phase II study
(H9B-MC-BCDF) in rheumatoid arthritis, 2008
- Figure: LY2127399 (IV): trial design of Phase II study (H9B-MC-BCDG) in
TNF-failure rheumatoid arthritis patients, 2009
- Figure: LY2127399 (SC): trial design of Phase II study (H9B-MC-BCDH) in
patients with rheumatoid arthritis despite ongoing methotrexate, 2009
- Figure: Actemra (tocilizumab): OPTION study design and results in
rheumatoid arthritis, 2008
- Figure: Actemra (tocilizumab): TOWARD study design and results in
rheumatoid arthritis, 2008
- Figure: Actemra (tocilizumab): RADIATE study design and results in
rheumatoid arthritis, 2008
- Figure: Actemra (tocilizumab): AMBITION study design and results in
rheumatoid arthritis, 2009
- Figure: Actemra (tocilizumab): LITHE study design and results in
rheumatoid arthritis, 2008
- Figure: Actemra/RoActemra SWOT analysis, 2009
- Figure: Datamonitor' s competitive positioning analysis of Actemra
(tocilizumab), 2009
- Figure: Canakinumab (ACZ885): Phase I/II clinical trial design and trial
data for in rheumatoid arthritis, 2008
- Figure: Denosumab (AMG162): Phase II trial design for rheumatoid
arthritis, 2008
- Figure: AMG108: Phase II clinical trial design and efficacy data in
rheumatoid arthritis patients, 2009
- Figure: LY2439821: Phase II clinical trial design and efficacy data in
rheumatoid arthritis, 2009
- Figure: ALD518: Clinical trial design of Phase II study in rheumatoid
arthritis, 2009
- Figure: AZD5672: clinical trial design of Phase IIb proof-of-concept study
of in rheumatoid arthritis, 2009
- Figure: Datamonitor drug assessment summary for kinase inhibitors in
development for rheumatoid arthritis, 2009
- Figure: CP-690,550: Phase II (A3921039) trial of four doses, in
combination with methotrexate, in Japanese rheumatoid arthritis patients with
an inadequate response to methotrexate, 2009
- Figure: CP-690,550: 12-week interim data from Phase II (A3921035) trial in
rheumatoid arthritis patients with an inadequate response to DMARDs, 2009
- Figure: CP-690,550:: SWOT analysis, 2009
- Figure: Datamonitor' s competitive positioning analysis of CP-690,550, 2009
- Figure: R788: TASKi3 Phase IIb clinical trial design and key results in
rheumatoid arthritis, 2009
- Figure: R788: Time course for the ACR20 response for R788 and placebo in
the TASKi3 trial in rheumatoid arthritis, 2009
- Figure: R788: TASKi2 Phase IIb clinical trial design and summary of
results in rheumatoid arthritis, 2009
- Figure: R788: TASKi1 Phase IIa clinical trial design and summary of
results in rheumatoid arthritis, 2008
- Figure: R788 SWOT analysis, 2009
- Figure: Datamonitor' s competitive positioning analysis of R788, 2009
- Figure: Masitinib (AB1010): Design of the ongoing Phase II (AB06010) trial
in rheumatoid arthritis, 2009
- Figure: Masitinib (AB1010): Design of the completed Phase IIa (AB04012)
trial in rheumatoid arthritis, 2006
- Figure: ARRY162: Phase II clinical trial (ARRAY-162-201) design in
rheumatoid arthritis, 2009
- Figure: BMS-582949: Phase II clinical trial design in rheumatoid
arthritis, 2009
- Figure: BMS-582949: Phase I trial design and results highlights, 2008
- Figure: INCB18424: Phase IIa clinical trial design in rheumatoid
arthritis, 2008
- Figure: INCB28050: Phase II clinical trial design in rheumatoid arthritis,
2009
- Figure: PH797804: Phase II trial as a monotherapy in rheumatoid arthritis
patients who failed DMARDs, 2008
- Figure: PH797804: Phase II trial (A6631005) as a combination therapy with
methotrexate in rheumatoid arthritis, 2008
- Figure: VX702: Clinical trial design summary for Phase II trials in
rheumatoid arthritis, 2009
- Figure: dnaJp1: Phase II clinical trial design for in rheumatoid
arthritis, 2007
- Figure: CH1504: Phase II trial design showing efficacy and safety results
in rheumatoid arthritis, 2009
- Figure: Tranilast: Nuon Therapeutics' Phase II trial in combination with
methotrexate in rheumatoid arthritis, 2009
- Figure: MM093: Phase II clinical trial design in rheumatoid arthritis, 2008
- Figure: RWJ-445380: Phase IIa clinical trial in active rheumatoid
arthritis patients despite methotrexate, 2008
- Figure: LX-2931 (LX-3305): Phase II trial in rheumatoid arthritis, 2009
- Figure: TAK783: Phase II clinical trial design in rheumatoid arthritis,
2009
- Figure: Early-stage projects, split by drug class, in development for
rheumatoid arthritis, 2009
- Figure: Early phase kinase inhibitors in development for rheumatoid
arthritis split by target, 2009
- Figure: Role of macrophages in model of rheumatoid arthritis pathogenesis
|
Related Report
|
View Cart
